Question 1

A 38-year-old man with bipolar I disorder has been cycling between depressive and manic episodes despite lithium monotherapy. He is currently in a depressive episode. He gained 30 pounds on quetiapine during a previous manic episode and refuses to take it again. He has no cardiac risk factors and no CYP3A4-interacting medications. Which of the following agents best addresses his clinical situation?

Accepted Answer

Cariprazine is one of very few agents with FDA approval for both bipolar I depression and bipolar mania, making it specifically suited for patients who cycle between episodes and need coverage across both poles. Its lower metabolic risk profile on average addresses this patient's justified concern about weight gain from quetiapine. It can be used adjunctively with his existing lithium. The trade-offs (ultra-long time to full effect, akathisia risk) should be discussed, and expectations set that improvement may take several weeks due to the long active metabolite half-life.

Answer A introduces the most metabolically burdensome bipolar depression option for a patient who already refused quetiapine for weight gain. Answer C has two problems: lamotrigine requires slow titration (cannot start at 200mg without risking Stevens-Johnson syndrome) and its evidence for acute bipolar depression is modest (it is better established for maintenance prevention). Answer D incorrectly claims valproate superiority for bipolar depression; valproate has limited evidence for the depressive phase.

Question 2

A patient with schizophrenia on cariprazine 3mg daily for 3 weeks develops moderate akathisia (pacing, inability to sit still, distressing inner restlessness). The treatment team stops cariprazine and starts risperidone 2mg the next day. One week later, the akathisia is unchanged and the patient now also reports feeling "slowed down" and stiff. What happened?

Accepted Answer

The ultra-long half-life of DDCAR (cariprazine's primary active metabolite, with a half-life on the order of weeks) means active cariprazine metabolites remain in the system for weeks after discontinuation. One week after stopping, the patient still has substantial cariprazine activity. The akathisia from cariprazine has not resolved because the drug has not washed out. The "slowed down and stiff" symptoms are likely drug-induced parkinsonism from risperidone, which is now producing its own D2-blockade effects layered on top of residual cariprazine activity. The correct approach would have been to start risperidone at a lower dose and titrate slowly, anticipating weeks of overlapping cariprazine activity during the washout.

Answer A is possible in isolation but does not explain why the original akathisia is unchanged (if cariprazine were already cleared, stopping it should have resolved the cariprazine-related akathisia). Answer C is an overreaction to the described symptoms (akathisia plus mild parkinsonism, no fever, rigidity, autonomic instability, or altered mental status). Answer D is pharmacokinetically wrong (DDCAR's half-life is on the order of weeks; one week is far too early for meaningful clearance).

Question 3

A psychiatrist is choosing between aripiprazole and cariprazine for a 42-year-old patient with schizophrenia whose primary burden is negative symptoms (anhedonia, social withdrawal, avolition) rather than positive symptoms (which are well-controlled on her current low-dose haloperidol but she has significant negative symptom burden). She has no metabolic concerns and tolerates both activation and mild akathisia. Which agent has the stronger pharmacological rationale for negative symptoms, and why?

Accepted Answer

Cariprazine has the stronger pharmacological rationale for negative symptoms, though the evidence base is still developing. Its approximately 10-fold higher affinity for D3 receptors over D2 targets a receptor concentrated in reward and motivation circuits (ventral striatum, prefrontal cortex) that are implicated in the motivational deficits underlying negative symptoms. Head-to-head data against risperidone has shown advantages on negative symptom measures with cariprazine. The caveat: the effect sizes are modest and separating primary from secondary negative symptoms in clinical trials is methodologically challenging. This is an area where pharmacological rationale is ahead of definitive clinical proof.

Answer A is partially true (aripiprazole is more established overall) but it does not have the D3-specific rationale or the head-to-head negative symptom trial data. Answer C is overly nihilistic (negative symptoms are difficult to treat but not completely unresponsive to pharmacological intervention). Answer D is counterproductive (higher-dose D2 blockade in the mesocortical pathway is more likely to worsen negative symptoms than improve them, and increases EPS risk in the nigrostriatal pathway).

Cariprazine

Side Effects Worth Knowing

Akathisia: the primary tolerability concern

Insomnia: common, related to activating profile

Nausea: common, usually transient

EPS (other than akathisia): low rate

Weight: lower metabolic risk on average

Metabolic effects: minimal

Prolactin: usually low impact

QTc prolongation: no meaningful signal in trials

See This Medication in Action

References & Further Reading